AnalystBook Research · Company Intelligence

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

PACBNasdaq

Built from PACIFIC BIOSCIENCES OF CALIFORNIA, INC.'s own SEC filings · updates as new filings land · sources cited throughout

or browse all covered companies

The read at a glance

Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.

  • Distress risk · Altman Z-Score -13.28 distress zone — historically elevated failure riskWatch
  • Earnings-manipulation signal · Beneish M -5.14 no flag raisedOK
  • Earnings quality 64/100 worth a closer lookWatch

Where the revenue comes from

Fiscal 2025, as PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reports it. History and quarterly detail are in the app.

  • Product revenue$135.8M
  • Service and other revenue$24.2M

Leadership changes

From PACIFIC BIOSCIENCES OF CALIFORNIA, INC.'s own filings, the day they're filed.

  • Michele Farmer · Chief Accounting Officer · departureeff. 2026-03-02
  • Jim R. Gibson · Chief Financial Officer · appointmenteff. 2025-03-24
  • Christopher M. Smith · director · appointmenteff. 2025-01-30

Latest filings

  • 10-Q · Quarterly report2026-08-06
  • 8-K · Company announcement2026-08-05
  • 8-K · Company announcement2026-07-09
  • 8-K · Company announcement2026-06-04
  • 10-Q · Quarterly report2026-05-08
In the full recordFree for 14 days
  • The filings, readable — with what changed vs the prior year highlighted🔒
  • Full financial statements, industry-aware, sources cited throughout🔒
  • Forensic score history & components — the trend, not one year🔒
  • Ownership: insider buys/sells, clusters, activist stakes🔒
  • Ana — ask about PACIFIC BIOSCIENCES OF CALIFORNIA, INC., every answer cited to the official filings🔒
  • The Intelligence Brief — added when PACIFIC BIOSCIENCES OF CALIFORNIA, INC.'s brief passes our SEC-figure check🔒

Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.

14-day free trial, no credit card. For research purposes only; not investment advice.